Sugi Predict

Sugi Predict / Compounds / SCHEMBL16009685

SCHEMBL16009685

SCHEMBL16009685

C[C@H]1CN(C)CCN1C(=O)Cl

nearest known ligand 0.39

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ TSHR P16473 3/20 0.38
▸ MAPT P10636 1/20 0.38
▸ GAA P10253 1/20 0.35
▸ SMN1; SMN2 Q16637 2/20 0.34
▸ LMNA P02545 1/20 0.34
▸ ALOX15 P16050 1/20 0.34
▸ HSD17B10 Q99714 1/20 0.34
▸ HSP90AA1 P07900 2/20 0.34
▸ GSK3B P49841 1/20 0.33
▸ DYRK1A Q13627 1/20 0.33
▸ CYP1A2 P05177 1/20 0.32
▸ TDP1 Q9NUW8 1/20 0.32
▸ GRM1 Q13255 2/20 0.32
▸ HSD11B1 P28845 1/20 0.32
▸ PRKCB P05771 1/20 0.31
▸ SMYD3 Q9H7B4 1/20 0.31
▸ HTT P42858 1/20 0.30
▸ L3MBTL1 Q9Y468 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21885560 1.00 TSHR (0.38) TSHRMAPTGAASMN1; SMN2LMNA
SCHEMBL16009686 1.00 TSHR (0.38) TSHRMAPTGAASMN1; SMN2LMNA
SCHEMBL3829548 0.81 TSHR (0.39) TSHRMAPTGAASMN1; SMN2LMNA
SCHEMBL9446411 0.81 TSHR (0.39) TSHRMAPTGAASMN1; SMN2LMNA
SCHEMBL799196 0.81 CYP1A2 (0.43) TSHRMAPTGAASMN1; SMN2LMNA
SCHEMBL4248088 0.81 TSHR (0.39) TSHRMAPTGAASMN1; SMN2LMNA
SCHEMBL799032 0.81 CYP1A2 (0.43) TSHRMAPTGAASMN1; SMN2LMNA
SCHEMBL357615 0.81 CYP1A2 (0.43) TSHRMAPTGAASMN1; SMN2LMNA
SCHEMBL11069033 0.79 — —
Hydrochloric Acid SCHEMBL4246521 0.79 TSHR (0.38) TSHRMAPTGAASMN1; SMN2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-122029158-A EGFR inhibitors 缆图药品公司 2026-05-12 — — CN disclosed
US-20250236608-A1 EGFR INHIBITORS BLUEPRINT MEDICINES CORPORATION 2025-07-24 — — US disclosed
WO-2025080784-A1 EGFR INHIBITORS BLUEPRINT MEDICINES CORPORATION (US) 2025-04-17 — — WO disclosed
EP-4504719-A1 EGFR INHIBITORS Blueprint Medicines Corporation (US) 2025-02-12 — — EP disclosed
CN-119325471-A EGFR inhibitors 缆图药品公司 2025-01-17 — — CN disclosed
WO-2023196283-A1 EGFR INHIBITORS BLUEPRINT MEDICINES CORPORATION (US) 2023-10-12 — — WO disclosed
CN-112996784-B Indole derivatives and their use in medicine 北京越之康泰生物医药科技有限公司 2023-05-30 — — CN disclosed
US-11358949-B2 Carbamate and urea compounds as multikinase inhibitors ANGEX PHARMACEUTICAL, INC. (US) 2022-06-14 — — US disclosed
EP-3342770-B1 QUINAZOLINE INHIBITORS OF ACTIVATING MUTANT FORMS OF EPIDERMAL GROWTH FACTOR RECEPTOR ASTRAZENECA AB (SE) 2022-03-30 — — EP disclosed
CN-112996784-A Indole derivatives and their use in medicine 北京越之康泰生物医药科技有限公司 2021-06-18 — — CN disclosed
US-20150320751-A1 Quinazoline Inhibitors of activating mutant forms of Epidermal Growth Factor Receptor ASTRAZENECA AB (SE) 2015-11-12 — — US disclosed
US-20150320751-A1 Quinazoline Inhibitors of activating mutant forms of Epidermal Growth Factor Receptor ASTRAZENECA AB (SE) 2015-11-12 — — US disclosed
US-20150320751-A1 Quinazoline Inhibitors of activating mutant forms of Epidermal Growth Factor Receptor ASTRAZENECA AB (SE) 2015-11-12 — — US disclosed
US-9066979-B2 Quinazoline inhibitors of activating mutant forms of epidermal growth factor receptor ASTRAZENECA AB (SE) 2015-06-30 — — US disclosed
US-9066979-B2 Quinazoline inhibitors of activating mutant forms of epidermal growth factor receptor ASTRAZENECA AB (SE) 2015-06-30 — — US disclosed
US-9066979-B2 Quinazoline inhibitors of activating mutant forms of epidermal growth factor receptor ASTRAZENECA AB (SE) 2015-06-30 — — US disclosed
WO-2014135876-A1 QUINAZOLINE INHIBITORS OF ACTIVATING MUTANT FORMS OF EPIDERMAL GROWTH FACTOR RECEPTOR ASTRAZENECA AB (SE) 2014-09-12 — — WO disclosed
US-20140255428-A1 Quinazoline Inhibitors of activating mutant forms of Epidermal Growth Factor Receptor ASTRAZENECA AB (SE) 2014-09-11 — — US disclosed
US-20140255428-A1 Quinazoline Inhibitors of activating mutant forms of Epidermal Growth Factor Receptor ASTRAZENECA AB (SE) 2014-09-11 — — US disclosed
US-20140255428-A1 Quinazoline Inhibitors of activating mutant forms of Epidermal Growth Factor Receptor ASTRAZENECA AB (SE) 2014-09-11 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150320751-A1 Quinazoline Inhibitors of activating mutant forms of Epidermal Growth Factor Receptor EGFR, ABL1, ERBB2 TSHR 2333/4885MAPT 4161/4885GAA 1522/4885
US-20250236608-A1 EGFR INHIBITORS EGFR, ERBB2, ERBB3 TSHR 976/4885MAPT 2806/4885GAA 1195/4885
US-11358949-B2 Carbamate and urea compounds as multikinase inhibitors UCK2, ULK2, CDK9 TSHR 4165/4885MAPT 1309/4885GAA 697/4885
US-20140255428-A1 Quinazoline Inhibitors of activating mutant forms of Epidermal Growth Factor Receptor EGFR, ERBB2, ABL1 TSHR 2349/4885MAPT 4146/4885GAA 1637/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.